Type 1 diabetes can’t be prevented or cured. However, it can be detected early through autoantibody screening before any noticeable symptoms arise, before insulin is required, and potentially before any serious complications occur. One such complication is diabetic ketoacidosis (DKA), a serious healthcare crisis that can be life-threatening. Early screening may help people potentially reduce their risk of going through DKA by up to 50%.

There’s a powerful social movement underway called “The 1 Pledge” that includes diverse voices of the type 1 diabetes community. The goal of the movement is to take action and get screened. Anyone can be screened for type 1 diabetes-related autoantibodies. By getting screened for type 1 diabetes early, people may give themselves and their families more time to prepare and plan for the future.

In an effort to spread the word about The 1 Pledge movement and the importance of screening for type 1 diabetes ahead of April 15 (Type 1 Diabetes Day), we invite you to join Dr. Michael B. Natter – a leading, New York-based Endocrinologist (who specializes in treating people with diabetes)

Dr. Natter has type 1 diabetes himself, having been diagnosed at age nine. Dr. Natter will discuss risk factors for type 1 diabetes and who should get screened. He will also talk about The 1 Pledge and the power of creating a plan of action to get screened, from his perspective as both a healthcare provider and a person living with type 1 diabetes.

Interview is courtesy: Sanofi

#diabetes #disease #screenfortype1 #thepledge #sanofi #type1 #insulin #diabetic #therapy #lifelongtherapy #ipledge #the1pledge #families #endocrinologist #diaagnosed #healthcare

The post TYPE 1 DIABETES IS ON THE RISE IN THIS COUNTRY. CURRENTLY, ABOUT 1.24 MILLION AMERICANS LIVE WITH THE DISEASE, AND THAT NUMBER IS EXPECTED TO GROW TO FIVE MILLION BY 2050… appeared first on Good News!.

What are diabetes home tests?

Testing blood glucose, also known as blood sugar, is an essential part of your diabetes care plan.

Depending on your current condition, you may need to visit your doctor several times a year for formal testing, according to the American Diabetes Association. You may also need to reach out to your doctor for preventive testing, such as cholesterol checks and eye exams.

While staying in touch with your doctor is important for staying on top of your treatment plan, you can and should test your blood sugar on your own as long as your healthcare team advises you to.

Self-monitoring your blood glucose may be vital to your treatment. Testing your own levels allows you to learn how to manage your blood sugar regardless of the time of day or where you are.

Learn how these tests work and talk with your doctor about the benefits of self-monitoring.

The post The latest diabetes stories for you appeared first on Good News!.

37.3 million Americans – about 1 in 10 – have diabetes, according to the Centers for Disease Control and Prevention.1 The chronic disease can take a severe toll on an individual’s quality of life, affecting their physical, mental, and emotional well-being.

Some people with diabetes also suffer from painful diabetic peripheral neuropathy (DPN), a deliberating and progressive neurological disorder that affects approximately 30% of the diabetes patient population.2 DPN can be caused when high blood sugar (glucose) damages nerves, most often in the legs and feet, leading to chronic numbness and burning or stabbing pain.

Dr. Silky Patel, an interventional spine, sports and pain management physician in Houston, will be available to discuss the impact of DPN and the latest innovative way to treat the condition. Ms. Farrah Stewart, a patient of Dr. Patel’s with painful DPN and a spinal cord stimulator, will join in the conversation to share her experience and the impact spinal cord stimulation has made in her life.

Conventional medical approaches, such as compression socks, topical creams, and prescription medications, do not always resolve DPN symptoms. But there is hope for these patients. Recently, spinal cord stimulation (SCS) has been FDA approved as a therapy for treatment of painful DPN of the lower extremities. A National Institutes of Health review finds that spinal cord stimulation for painful DPN is an effective and safe option for treatment.3

SCS is a proven long-term and effective therapy for managing chronic pain.4,5
• A spinal cord stimulator is an implantable medical device that works by disrupting the pain signals traveling between the spinal cord and the brain.
• Patients with DPN are 17 times more likely to experience significant pain relief if treated with SCS compared to conventional treatment.6,7,8
• 86% of patients experienced treatment success after receiving SCS therapy for one year.9
• SCS can offer proven long-term therapy for managing chronic pain, with the majority of patients experiencing meaningful pain relief through five years of treatment using the device.9
Interview is courtesy: Medtronic

1. Centers for Disease Control and Prevention. The Facts, Stats, and Impacts of Diabetes. https://www.cdc.gov/diabetes/library/spotlights/diabetes-facts-stats.html
2. Sloan G, Alam, U, Selvarajah D, Tesfaye S. The Treatment of Painful Diabetic Neuropathy. Current Diabetes Reviews. July 2021
3. Henson JV, Varhabhatla NC, Bebic Z, Kaye AD, Yong RJ, Urman RD, Merkow JS. Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy: A Systematic Review. Pain Ther. 2021 Dec;10(2):895-908. doi: 10.1007/s40122-021-00282-9. Epub 2021 Jul 10. PMID: 34244979; PMCID: PMC8586096.
4. Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. Neurosurgery. 2008;63(4):762-770. Discussion: 770.
5. Kemler MA, de Vet HC, Barendse GA, van den Wildenberg FA, van Kleef M. Effect of spinal cord stimulation for chronic complex regional pain syndrome type 1: five-year final follow-up of patients in a randomized controlled trial. J Neurosurg. 2008;108(2):292-298.
6. Medtronic. Medtronic Pain Therapy Clinical Summary M221494A016 Rev B. United States; 2022
7. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014 Nov;155(11):2426-31.
8. Slangen R, Schaper N, Faber C, et al. Spinal Cord Stimulation and Pain Relief in Painful Diabetic Peripheral Neuropathy: A Prospective Two-Center Randomized Controlled Trial. Diabetes Care. 2014;37:3016-3024.
9. Van Beek M, Geurts J, Slangen R, et al. Severity of Neuropathy Is Associated With Long-term Spinal Cord Stimulation Outcome in Painful Diabetic Peripheral Neuropathy: Five-Year Follow-up of a Prospective Two-Center Clinical Trial. Diabetes Care. 2018;41:32–38.

#dpn #diabetes #diabetesawarenessmonth #diabetic #pain #silkypatel #farrahstewart #painmanagement

The post November Is Diabetes Awareness Month LEARN ABOUT AN INNOVATIVE OPTION FOR DIABETIC PATIENTS TO CONTROL DEBILATING PAIN appeared first on Good News!.

More than 34 million Americans – just over 1 in 10 – have diabetes, and neuropathic pain associated with diabetic peripheral neuropathy of the feet, or more commonly referred to as diabetic nerve pain, is one of its most common complications.

The painful symptoms associated with this nerve damage include numbness, tingling, as well as burning, shooting or stabbing sensations that most often affect the lower extremities.

It is a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 2021 and is expected to double by 2030.

Lindsay Colbert, Executive Director of The Foundation for Peripheral Neuropathy, and Dr. Rodica Pop-Busui, MD, PhD, Professor of Internal Medicine, Metabolism, Endocrinology and Diabetes and Vice Chair Clinical Research, Department of Internal Medicine at the University of Michigan, Ann Arbor will be available to talk about the findings from a new national survey of patients that captured beliefs, perspectives and attitudes towards their diabetic nerve pain.

A key finding from the survey revealed an overwhelming 71% of patients desire change, and are seeking better treatments and a future with less pain. Furthermore, over a third of respondents reported needing to rest more; the most frequently reported necessary life-style change due to their pain.

Key Facts and Figures:

The lack of effective, innovative treatment options have left many patients with a significant unmet medical need

Two in five patients had to visit three or more doctors before getting the right diagnosis for their pain

58% of patients are not satisfied with the current treatment plan for their diabetic nerve foot pain

Interview is courtesy of Averitas Pharma, Inc.

https://www.averitaspharma.com/
https://www.nervepainandme.com/

#lindsay #colbert #rodica #pop #busui #phd #md #neuropathy #foundation #painful #symptoms #neuropathic #pain #diabetic #nerve #numbness #averitas #pharma #medical #medicine #pop-busui #me #patients

The post Diabetic Nerve Pain will Affect Approximately 5 Million Americans in 2021 appeared first on Good News!.

Find Out More About this Condition. Capsian Patch, … can be considered. a specific approved product is Qutinza
More than 34 million Americans – just over 1 in 10 – have diabetes1, and neuropathic pain associated with diabetic peripheral neuropathy of the feet, or more commonly referred to as diabetic nerve pain, is one of its most common complications.2
The painful symptoms associated with this nerve damage include numbness, tingling, as well as shooting or stabbing sensations that most often affect the lower extremities.3
Itis a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20204 and is expected to double by 2030.5
Joining us now to discuss neuropathic pain associated with diabetic peripheral neuropathy – or diabetic nerve pain – and this newly approved treatment option is Dr. David Simpson, Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York City.
Key Facts and Figures:
• The lack of effective, innovative treatment options has left many patients with a significant unmet medical need.
• The condition is more common in patients with type 2 diabetes and increases with age and duration of disease.
When you book a window, we’ll provide you with guest bio & suggested questions. The interview is courtesy of Averitas Pharma, Inc.
References:
1. CDC Division of Diabetes Translation, National Diabetes Statistics Report, 2020. https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html#:~:text=New%20in%202020%2C%20the%20report,1%20in%203%E2%80%94have%20prediabetes. Accessed July 6, 2020
2. University of Chicago Center for Peripheral Neuropathy. Types of peripheral Neuropathy. http://peripheralneuropathycenter.uchicago.edu/learnaboutpn/typesofpn/diabetes/diabetes.shtml. Accessed July 6,2020
3. American Diabetes Association. Peripheral NeuorapthyOverview. https://www.diabetes.org/diabetes/complications/neuropathy/peripheral-neuropathy.Accessed July 17, 2020
4. LTP2020-2030: ADDRESSABLE POPULATIONS BY CONDITION (PDPN, PSNP, PHN, CINP).Company data on file. April 30, 2020.
5. Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L.,Tai, K.-S., & Stacey, B. (2005). Pain Severity in Diabetic Peripheral Neuropathy is Associated with patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. Journal of Pain and Symptom Management, 30(4),374-385. doi:10.1016/j.jpainsymman.2005.04.009.
https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html
6. CDC,Behavioral Risk Factor Surveillance System, 2018
7. America’sHealth Rankings. United Health Foundation.https://www.americashealthrankings.org/explore/annual/measure/Diabetes. Accessed July 13, 2020

The post DIABETIC NERVE PAIN WILL AFFECT APPROXIMATELY 5 MILLION AMERICANS IN 2020 appeared first on Good News!.